Doctors call for curb on drug company profiteering
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.A group of 20 leading doctors today appeals to the Prime Minister to curb profiteering by drug companies that are exploiting a legal loophole to make millions of pounds from the NHS.
In an open letter published in the British Medical Journal, the hospital consultants accuse the companies of obtaining licences for existing drugs and then imposing massive rises in their price. In one case, a company making an intravenous version of the painkiller ibuprofen charges £6,575 per gram compared with 8 pence per gram for the tablet. Another case involves a drug for a rare muscle disorder which used to cost about £1,000 per patient a year. After a drug company modified it, the price rose to between £40,000 and £70,000 a year.
The price hikes are allowed under rules designed to encourage firms to develop treatments known as "orphan drugs" for rare conditions which it would not otherwise be economic for them to do. But many companies are modifying existing drugs, and obtaining a licence for orphan diseases which then gives them sole rights to supply the drugs and raise prices. A spokesperson for the Association of the British Pharmaceutical Industry said: "As orphan diseases involve small populations, it can be difficult to make a return on R&D investment."
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments